Abstract：
Growing concerns regarding the emergence of highly transmissible viral diseases highlight the urgent need to expand the repertoire of antiviral therapeutics. For this reason, new strategies for neutralizing and inhibiting these viruses are necessary. A promising approach involves targeting the glycans present on the surfaces of enveloped viruses. Lectins, known for their ability to recognize specific carbohydrate molecules, offer the potential for glycan-targeted antiviral strategies. Indeed, numerous studies have reported the antiviral effects of various lectins of both endogenous and exogenous origins. However, many lectins in their natural forms, are not suitable for use as antiviral therapeutics due to toxicity, other unfavorable pharmacological effects, and/or unreliable manufacturing sources. Therefore, improvements are crucial for employing lectins as effective antiviral therapeutics. A novel approach to enhance lectins\' suitability as pharmaceuticals could be the generation of recombinant lectin-Fc fusion proteins, termed \"lectibodies.\" In this review, we discuss the scientific rationale behind lectin-based antiviral strategies and explore how lectibodies could facilitate the development of new antiviral therapeutics. We will also share our perspective on the potential of these molecules to transcend their potential use as antiviral agents.
摘要：
对高度传染性病毒疾病的出现越来越多的关注凸显了扩大抗病毒疗法的迫切需要。出于这个原因,中和和抑制这些病毒的新策略是必要的。有希望的方法涉及靶向存在于包膜病毒表面上的聚糖。莱克汀,以识别特定碳水化合物分子的能力而闻名，提供聚糖靶向抗病毒策略的潜力。的确,许多研究报道了内源性和外源性来源的各种凝集素的抗病毒作用。然而,许多自然形式的凝集素，由于毒性，不适合用作抗病毒疗法，其他不利的药理作用，和/或不可靠的制造来源。因此,改进对于使用凝集素作为有效的抗病毒疗法至关重要。增强凝集素作为药物的适用性的新方法可能是产生重组凝集素-Fc融合蛋白，被称为“传道人”。“在这次审查中，我们讨论了基于凝集素的抗病毒策略背后的科学原理，并探讨了凝集素抗体如何促进新的抗病毒疗法的发展。我们还将分享我们对这些分子超越其作为抗病毒剂的潜在用途的潜力的看法。
